Contemporary Issues in Lung CancerJones & Bartlett Publishers, 2009 M02 12 - 364 pages In the United States, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death. Even more devastating is its five-year survival rate of only 15.8%. Despite these dismal facts, lung cancer receives little national attention and research and funding for lung cancer lags behind other cancers. The intent of Contemporary Issues in Lung Cancer: A Nursing Perspective Second Edition is to provide oncology nurses and healthcare professionals with in-depth information on the issues that surround this disease, so that they might impact both education and research and provide better care for their patients. |
From inside the book
Results 1-5 of 47
Page ii
... drug in the clinical setting, the health care provider or reader is responsible for determining FDA status of the drug, reading the package insert, and reviewing prescribing information for the most up-to-date recommendations on dose ...
... drug in the clinical setting, the health care provider or reader is responsible for determining FDA status of the drug, reading the package insert, and reviewing prescribing information for the most up-to-date recommendations on dose ...
Page 19
... drug resistance (Graziano, et al., 2001; Sekido, et al., 2005). KIT proto-onco- gene, another tyrosine kinases receptor, and its ligand are found in many small cell lung cancers (SCLC); however, targeted therapy for these re- ceptors ...
... drug resistance (Graziano, et al., 2001; Sekido, et al., 2005). KIT proto-onco- gene, another tyrosine kinases receptor, and its ligand are found in many small cell lung cancers (SCLC); however, targeted therapy for these re- ceptors ...
Page 25
... drug to treat an individual's cancer (Hsu, et al., 2008). Limitless. Replicative. Potential: Telomerase. While the genetics of lung cancer are being defined, other areas also are important in considering the development and progression of ...
... drug to treat an individual's cancer (Hsu, et al., 2008). Limitless. Replicative. Potential: Telomerase. While the genetics of lung cancer are being defined, other areas also are important in considering the development and progression of ...
Page 58
You have reached your viewing limit for this book.
You have reached your viewing limit for this book.
Page 68
You have reached your viewing limit for this book.
You have reached your viewing limit for this book.
Contents
Oncology Treatment Modalities | 45 |
Special Issues Facing Individuals with Lung Cancer | 117 |
Psychosocial Issues of Individuals with Lung Cancer | 231 |
Assistance and Resources for Individuals Facing Lung Cancer | 255 |
Media and Future Research Directions | 301 |
Index | 353 |
Other editions - View all
Common terms and phrases
adjuvant agents aprepitant associated bevacizumab breathing breathlessness Bruera carboplatin carcinoma cell lung cancer chemotherapy chronic cisplatin Clinical Oncology clinical trials combination diagnosis disease docetaxel dose drug dyspnea EGFR erlotinib etoposide evaluation evidence-based factors fatigue gefitinib gemcitabine gene improve increased individuals indoor radon Internet intervention irinotecan Journal of Clinical lung cancer patients Medicine ment metastatic months NCCN nicotine non-small cell lung NSCLC Nursing Forum Oncology Nursing Oncology Nursing Forum paclitaxel palliative palliative care patient navigation patients and families patients with lung pemetrexed phase postoperative potential pulmonary quit smoking radiation therapy radiotherapy radon randomized receptors regimen reported resection respiratory response rate risk role SCLC score screening Sekido side effects small cell lung smoking cessation stage strategies support group surgical survival rate Symptom Management Table tients tion tobacco topotecan toxicity treat treatment tumor versus vinorelbine weight loss